42
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset

ORCID Icon, , , , , ORCID Icon, ORCID Icon, & show all
Pages 191-205 | Received 15 Nov 2023, Accepted 27 Mar 2024, Published online: 24 Apr 2024

References

  • Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16(6):535–544. doi:10.2450/2017.0150-17
  • Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
  • Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487–493. doi:10.1111/hae.13998
  • National Bleeding Disorders Foundation. Hemophilia A. Available from: https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a. Accessed January 5, 2024.
  • Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus. 2019;17(5):378–384. doi:10.2450/2019.0253-18
  • Witmer C, Presley R, Kulkarni R, et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011;152(2):211–216. doi:10.1111/j.1365-2141.2010.08469.x
  • Bray G. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII. Ann Hematol. 1994;68(Suppl 3):S29–S34. doi:10.1007/BF01774527
  • Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–435. doi:10.1046/j.1365-2516.2003.00780.x
  • Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014;12(Suppl 1):s319–s329. doi:10.2450/2013.0246-12
  • Zanon E, Iorio A, Rocino A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia. 2012;18(1):39–45. doi:10.1111/j.1365-2516.2011.02611.x
  • von Drygalski A, Kolaitis NA, Bettencourt R, et al. Prevalence and risk factors for hypertension in hemophilia. Hypertension. 2013;62(1):209–215. doi:10.1161/HYPERTENSIONAHA.113.01174
  • Pierre-Louis YS, Perla KMR, Perez GM, et al. The insurance coverage paradox - characterizing outcomes among dual-eligible hemorrhagic stroke patients. J Clin Neurosci. 2022;97:99–105 doi:10.1016/j.jocn.2021.12.023.
  • Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017;179(2):298–307. doi:10.1111/bjh.14844
  • Zwagemaker AF, Gouw SC, Jansen JS, et al. Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood. 2021;138(26):2853–2873. doi:10.1182/blood.2021011849
  • Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18(3):e140–e153. doi:10.1111/j.1365-2516.2012.02770.x
  • Arpey NC, Gaglioti AH, Rosenbaum ME. How socioeconomic status affects patient perceptions of health care: a qualitative study. J Prim Care Community Health. 2017;8(3):169–175. doi:10.1177/2150131917697439
  • Becker G, Newsom E. Socioeconomic status and dissatisfaction with health care among chronically ill African Americans. Am J Public Health. 2003;93(5):742–748. doi:10.2105/AJPH.93.5.742
  • National Academies of Sciences. Engineering, and Medicine. In: Baciu A, Negussie Y, Geller A, Weinstein JN, editors. Communities in Action: Pathways to Health Equity. Washington (DC): The National Academies Press; 2017.
  • Brackmann HH, White GC 2nd, Berntorp E, Andersen T, Escuriola-Ettingshausen C. Immune tolerance induction: what have we learned over time? Haemophilia. 2018;24(S3):3–14. doi:10.1111/hae.13445
  • Nakar C, Shapiro A. Hemophilia A with inhibitor: immune tolerance induction (ITI) in the mirror of time. Transfus Apher Sci. 2019;58(5):578–589. doi:10.1016/j.transci.2019.08.008
  • Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost. 2020;120(10):1357–1370. doi:10.1055/s-0040-1714279
  • Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. the hemophilia surveillance system project investigators. Am J Hematol. 1998;59(4):288–294. doi:10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I
  • Stieltjes N, Calvez T, Demiguel V, et al. Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death. Haemophilia. 2005;11(5):452–458. doi:10.1111/j.1365-2516.2005.01090.x